ArticleJournal of gastrointestinal cancer2023
Design and Characterization of Silver Nanoparticles of Different Species of Curcuma in the Treatment of Cancer Using Human Colon Cancer Cell Line (HT-29).
Article in Journal of gastrointestinal cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Recent Advancements in Drug Targeting for Ferroptosis as an Antitumor Therapy: Development of Novel therapeutics.Current cancer drug targets · 2026Review
- Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges.Frontiers in oncology · 2026Review
- Targeting the cGAS-STING Pathway in Gastrointestinal Cancers: Modulating Tumor-associated Inflammation for Therapeutic Effect.Current drug targets · 2026Review
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials.Frontiers in pharmacology · 2026Review
- Antibody-Drug Conjugates and Beyond: Next-Generation Targeted Therapies for Breast Cancer.Cancers · 2025Review
- Efficacy of curcumin-synthesized silver nanoparticles on MCF-7 breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Drug Targeting and Nanotherapeutic Advancement in the Treatment of Rheumatoid Arthritis: Recent Progress in Drug Delivery Systems.Current pharmaceutical biotechnology · 2025Review
- Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.Current pharmaceutical design · 2025Review
- A Review on Nanotechnologically Derived Phytomedicines for the Treatment of Hepatocellular Carcinoma: Recent Advances in Molecular Mechanism and Drug Targeting.Current drug targets · 2025Review
- Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.Current cancer drug targets · 2025Review
- Recent Advances and Clinical Approach to Cancer Treatment with Nanotechnology Derived Biomolecule.Pharmaceutical nanotechnology · 2025Review
- Herbal based nanoparticles as a possible and potential treatment of cancer: a review.Exploration of targeted anti-tumor therapy · 2025Review
- A Comprehensive Review on Novel Therapies for Gastrointestinal Cancers using Translational Platforms.Current pharmaceutical design · 2025Review
- Biosynthesis of silver nanoparticles from plant extracts: a comprehensive review focused on anticancer therapy.Frontiers in pharmacology · 2025Review
- Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.Current cancer drug targets · 2025Review
- Impact of metallic nanoparticles on gut microbiota modulation in colorectal cancer: A review.Cancer innovation · 2024Review
- Nanomaterials in Targeting Cancer Cells with Nanotherapeutics: Transitioning Towards Responsive Systems.Current pharmaceutical design · 2024Review
- Recent Advancement in Novel Wound Healing Therapies by Using Antimicrobial Peptides Derived from Humans and Amphibians.Current protein & peptide science · 2024Review
- Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.Current drug targets · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer is a deadly disease responsible for worldwide mortality; usually, middle- and low-income countries have been more affected by cancer and are responsible for 70% of deaths. The present study was performed with the aim to design silver nanoparticles using three species of Curcuma, i.e., Curcuma longa, Curcuma aromatica, and Curcuma caesia.
methodsThe rhizomes of different plants were extracted with ethanol. The rhizome extracts were used to prepare silver nanoparticles. It was optimized at different pH, silver ion concentrations, and concentrations of plant extracts. The anticancer activity of prepared nanoparticles of C. longa, C. aromatica, and C. caesia was evaluated on a human colon cancer cell line (HT-29) using sulforhodamine B (SRB) assay.
resultsThe percentage yield of C. longa, C. aromatica, and C. caesia was 11.34 g, 15.45 g, and 12.67 g, respectively. The results exhibited that the prepared nanoparticles were smooth and spherical. All the nanoparticles of rhizome extracts rescued the viability of HT-29 cells in a different extent. HT-29 cells were sensitive to prepared nanoparticles that induce more cytotoxicity towards cancer cells.
conclusionThus, the prepared silver nanoparticle of Curcuma species through green synthesis may help treat cancer with low toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.